Also, the intraperitoneal treatment of FGFC1 (10 mg/kg) reduced dermatologically placed PC9 cell growth via NF-κB signaling pathway inhibition in tumor xenografted mice and thus reduced tumor volume (Yan et al., 2021; Feng et al., 2022). This evidence concerns the gene NFKB1 and neoplasm.